Impact of TP53 on outcome of patients with myelofibrosis undergoing hematopoietic stem cell transplantation ashpublications.org/blood/article/…

NEW: with over 5 years of follow-up, sorafenib maintenance is associated with improved outcomes compared w/ non-maintenance in patients w/ FLT3-ITD AML undergoing allogeneic HSCT in a multicentre, randomised, ph 3 trial #leusm #bmtsm thelancet.com/journals/lanha…

If the reporter had just used some brains to search up average pay in the US and Australia to compare. But guess BBC News (UK) don't pay their reporters enough. I guess low pay is common across the island bbc.com/news/health-66…

Moving away from chemotherapy in newly diagnosed Philadelphia chromosome-positive B-cell acute lymphoblastic leukaemia onlinelibrary.wiley.com/doi/10.1111/bj… #leusm

Out now: our study of dual CAR T cells. In a heavily pre-treated cohort including 1/3 failing prior Kymriah, we achieved 1 yr EFS 60%. To date there have been no cases of cd19neg relapse, contrasting with our experience targeting cd19 alone ashpublications.org/blood/article/…

A British Society for Haematology Guideline: Diagnosis and management of thrombotic thrombocytopenic purpura and thrombotic microangiopathies BSH - Haematology buff.ly/3sHFew7

Very soon in Washington Post/NYT : The overt and proud display of religion by the leader of a global superpower will further strengthen the dominance of majoritarian Hinduism in India, a tool which the ruling party employs to oppress minority groups.

CONGRESS | #AMLAcademy23 Richard Dillon gives a whistlestop tour of trials investigating the role of MRD, covering how patients with NPM1 FLT3 ITD+ AML do not benefit from SCT, use of venetoclax for NPM1 molecular relapse, use of FLT3 inhibitors to reach transplantation & the use of

Great to see NICE approve the MAIA regime in England to follow the approval of the SMC in Scotland… Myeloma UK represents a huge step forward in frontline myeloma care for transplant ineligible patients

A New Hope: India's First Approved CAR-T Cell Therapy - No Longer Sci-Fi, Now a Reality! We are pleased to announce the receipt of a Marketing Authorization Approval from the CDSCO for NexCAR19. Check below link to find out the latest press release - linkedin.com/posts/immunoac…

Reaction of Liberals after Ram killed Raavana ? 1) And they Killed him: The Indian Express 2) Was Ram required to go down all the way to Lanka to pick a fight? Where is our hospitality, our culture? Why was Ravana being terrorized: BBC 3) India is not safe for women: The

Welcome to the first #EHACase of 2024! Can you determine the patient’s diagnosis from the information given? We'll return tomorrow with an explanation. This question is presented by Dr Umut Yilmaz. See you then! How do you like our cases? Tell us here: wkf.ms/3Pdq1uw

How I treat multiple myeloma in geriatric patients ow.ly/e1av50Qsm4M #geriatrichematology #lymphoidneoplasia #multiplemyeloma

Very excited to discuss how CARTs continue to change haematology, oncology and soon other fields

Research update: contrary to convention, B12 deficiency, not iron, is the top cause of anemia in pregnancy. Let's rethink supplementation strategies and prioritize B12 and Fe & FA for expectant moms battling anemia. link.springer.com/article/10.100…

More than 2 years work by the #European #workinggroup on #ALL. Resulted in 2 #guidelines in #Bloodjournal. Worth a read if you manage this disease

Diagnosis, prognostic factors, and assessment of ALL in adults: 2024 ELN recommendations from a European expert panel ow.ly/1ajH50RASCe #specialreport #lymphoidneoplasia

Some glazes can be amazing

Tandem Autologous Stem Cell Transplantation Does Not Benefit High-Risk Myeloma Patients In The Maintenance Era: Real-world Results From The Canadian Myeloma Research Group Database Transplantation and Cellular Therapy Journal astctjournal.org/article/S2666-…

Just out Nature Medicine meta-analysis >7600 CAR T pts led by David Cordas dos Santos & Kai Rejeski - Non-relapse mortality post CAR-T = 6.8% - highest w ciltacel (15%) & brexucel (10.6%) - axicel (7%) > tisa-/lisocel (4%) for LBCL - 51% of NRM deaths from infection nature.com/articles/s4159…